ArticlePloS one2026
Multi-objective QSAR prediction of ERα antagonists via SHAP-based interpretation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable QSAR and Complementary Docking for PARP1 Inhibitor Prioritization: Reliability Stratification and Near-Domain Screening.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To achieve a comprehensive evaluation of candidate drugs in terms of both biological activity and ADMET properties, this study proposes a two-stage predictive framework based on Quantitative Structure-Activity Relationship (QSAR) modeling integrated with machine learning techniques, elucidating the quantitative relationships between molecular structure and pharmacological properties. A novel Dual-Filter Feature Selection (DFFS) method integrates statistical analysis and feature importance scores derived from machine learning models. The averaged rankings are used to obtain a robust set of molecular descriptors. In the first stage, 20 key two-dimensional molecular descriptors were selected via DFFS from ERα antagonists. RF, XGBoost, LightGBM, and gcForest-were employed for activity prediction. Experimental results indicated LightGBM achieved the best performance, with MRE of 0.0775. The comparative experiment demonstrates that under the same LightGBM regression framework, DFFS outperformed its individual components-Mutual Information and XGBoost-as well as the high-dimensional features generated by ChemBERTa. In the second stage, based on 40 descriptors selected by DFFS, a stacking model was constructed to perform multitask prediction of ADMET properties, ensuring that high-activity candidate compounds also exhibit favorable profiles in absorption, distribution, metabolism, excretion, and toxicity. The AUC scores for all five ADMET models exceeded 0.95. To elucidate the molecular mechanisms and interpret the model decisions, we applied Phi coefficient analysis to assess inter-property correlations and SHAP analysis to identify key molecular features governing compound activity. Furthermore, molecular docking was performed to evaluate the binding affinity of highly active compounds towards the target protein, thereby providing quantitative validation of the predicted biological activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.